Patients who received therapy with ICI as a first-line systemic treatment (28.6%) were mainly chosen based on their PDL-1 score (mainly NSCLC with a PDL-1 expression ≥50% (37.5%)) and/or tumor entity (mainly malignant melanoma (25%), urogenital tract (16.7%) and other malignancies, all of these being merkel cell carcinomas (12.5%)). This evidence concerns the gene CD274 and neoplasm.